# Report of the 2023 Mary Tyler Moore Vision Initiative Workshop

## TL;DR

Experts discussed new approaches to treat and diagnose diabetic retinal disease to improve patient care and drug development.

## Contribution

The paper emphasizes the need for a public-private consortium to advance diabetic retinal disease research and clinical endpoints.

## Key findings

- Updating the DRD staging system and severity scale is a key project for MTM Vision.
- Establishing a human ocular biorepository is highlighted as a critical resource.
- Validating clinical endpoints and biomarkers is essential for accelerating drug development.

## Abstract

The Mary Tyler Moore Vision Initiative (MTM Vision) Diabetic Retinal Disease (DRD) Clinical Endpoints Workshop was held on November 14, 2023. More than 130 clinicians, scientists, and representatives from funding and regulatory agencies, diagnostic, therapeutic, and biotech industry and patient advocates discussed the needs for new diagnostic and therapeutic approaches to preserve and restore retinal neurovascular unit integrity in people with diabetes. MTM Vision projects, notably updating the DRD staging system and severity scale, establishing a human ocular biorepository and resource, and validating useful clinical endpoints and biomarkers to accelerate development of new drugs and improve patient care were emphasized. A public-private consortium is essential to fulfill the objectives of MTM Vision for the benefit of persons with diabetes.